Moderna COVID Vaccine’s Myocarditis Risk Has Improved With Time, US FDA Says

 
• By Sue Sutter

‘Robust results’ from recent US surveillance studies show slight decreases in the myocarditis risk differential between the Moderna and Pfizer/BioNTech vaccines, agency says in briefing documents for panel review of Moderna’s pediatric EUA request.

Hour glass
The myocarditis risk differential for Moderna's vaccine relative to Pfizer/BioNTech's is looking better with the passage of time and more surveillance data. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers